[Notes on the HOPE-3 study]

Area of Science:

• Cardiovascular Medicine
• Preventive Cardiology
• Pharmacology

Background:

• Cardiovascular diseases remain a leading cause of mortality globally.
• Primary prevention strategies are crucial for reducing cardiovascular event incidence.
• The HOPE-3 trial investigated the efficacy of statins and antihypertensives in primary prevention.

Purpose of the Study:

• To evaluate the effect of statin and antihypertensive drug (candesartan and hydrochlorothiazide) "polypill" therapy on cardiovascular events in individuals at risk but without established cardiovascular disease.
• To assess whether the treatment effects varied across different ethnic populations.
• To determine the role of these medications in primary cardiovascular prevention.

Main Methods:

• The HOPE-3 study enrolled men over 55 and women over 65 years old without a history of cardiovascular disease.
• Participants received a "polypill" containing a statin and/or antihypertensive drugs (candesartan and hydrochlorothiazide).
• The study analyzed cardiovascular event rates and stratified outcomes by ethnic groups across six continents.

Main Results:

• Statin treatment demonstrated a statistically significant reduction in cardiovascular events (p = 0.002).
• Antihypertensive medication (candesartan and hydrochlorothiazide) did not significantly reduce the incidence of cardiovascular events in this population.
• The beneficial effect of statin treatment was consistent across all studied ethnic groups.

Conclusions:

• Statin therapy is effective in reducing cardiovascular events for primary prevention in at-risk individuals.
• Routine use of antihypertensive medication as tested in HOPE-3 did not provide significant cardiovascular event reduction in this primary prevention cohort.
• The efficacy of statin therapy for primary prevention is universal across diverse ethnic backgrounds.